Andy Schwab

Skye Bioscience, Inc. (OTCQB: SKYE) has undertaken a strategic initiative that expands the company's resources and technologies focused on developing therapeutic products focused on the endocannabinoid system ("ECS"). Skye raised $17 million in new capital and acquired Bird Rock Bio...